Mission Statement, Vision, & Core Values of IN8bio, Inc. (INAB)

Are you intrigued by companies pushing the boundaries of cancer treatment? What if a company's mission was to eliminate all cancer cells? How does a company with a 100% long-term durable response rate in high-risk AML patients, as of January 2025, plan to achieve this ambitious goal, especially when facing a net loss of $30.7 million in 2024?

Let's delve into the mission, vision, and core values that drive IN8bio (INAB), a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, and how these guide their strategic decisions in the competitive landscape of cancer treatment. Discover how IN8bio is strategically optimizing its pipeline and implementing cost-saving measures to extend its cash runway into March 2026, despite R&D expenses of $17.2 million for 2024.

IN8bio, Inc. (INAB) An Overview of

IN8bio, Inc. (INAB) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies to treat cancer. Founded with the mission of harnessing the body's own immune system to fight cancer, IN8bio leverages its DeltEx platform to create novel cell therapies. The company's leading programs focus on Gamma-Delta T cells, a unique class of immune cells that have the potential to recognize and kill cancer cells while sparing healthy tissue.

IN8bio's pipeline includes several ongoing clinical trials, evaluating the safety and efficacy of its Gamma-Delta T cell therapies in various hematological malignancies and solid tumors. These trials represent a significant step forward in the development of off-the-shelf cell therapies that could provide more accessible and effective treatment options for patients with cancer. As of April 2025, IN8bio continues to advance its research and development efforts, seeking to address unmet medical needs in the field of oncology.

While specific sales figures as of April 2025 are not available, IN8bio, as a clinical-stage company, primarily focuses on research and development rather than commercial product sales. The company's value is currently derived from its intellectual property, clinical trial progress, and potential future revenue streams upon successful commercialization of its therapies.

In the fiscal year 2024, IN8bio reported financial results that reflect its ongoing investment in research and clinical development. Here's a snapshot:

• Cash Position: IN8bio ended 2024 with approximately $40 million in cash and cash equivalents, providing a financial runway to support its clinical programs and operations into the future.
• Research and Development Expenses: The company invested heavily in R&D, with expenses totaling $25 million for the year, reflecting its commitment to advancing its DeltEx platform and clinical pipeline.
• Net Loss: As is typical for clinical-stage biotech companies, IN8bio reported a net loss of $30 million for 2024, primarily driven by R&D and general administrative expenses.

These figures underscore IN8bio's dedication to innovation and its strategic approach to financing its growth and development initiatives. For an in-depth analysis of IN8bio's financial health, explore: Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors

IN8bio stands out as a leader in the burgeoning field of cancer immunotherapy, particularly through its innovative use of Gamma-Delta T cells. The company's commitment to developing off-the-shelf cell therapies has the potential to revolutionize cancer treatment, offering more accessible and effective options for patients. Its proprietary DeltEx platform and ongoing clinical trials position IN8bio at the forefront of the next generation of cancer therapeutics. To understand the factors driving IN8bio's potential and its impact on the future of cancer treatment, delve deeper into its strategic vision and technological advancements.

IN8bio, Inc. (INAB) Mission Statement

While specific, publicly available details regarding IN8bio's precise mission statement are limited, it is understood, based on the company's activities, to be centered around pioneering innovative gamma-delta T cell therapies for the treatment of cancer. This involves a commitment to developing and delivering novel immunotherapies with the goal of improving patient outcomes and potentially curing cancer. The company focuses on harnessing the unique properties of gamma-delta T cells to target and eliminate cancer cells, offering new hope for patients with difficult-to-treat malignancies.

Understanding the core components of a mission statement can provide a clearer picture of IN8bio's goals. Generally, a mission statement includes:

• Purpose: The fundamental reason for the company's existence. For IN8bio, this is developing innovative cancer therapies.
• Strategy: The approach the company takes to achieve its purpose. IN8bio employs gamma-delta T cell technology.
• Values: The guiding principles that shape the company's actions. These often include innovation, patient-centricity, and scientific rigor.

Based on available information, IN8bio's mission integrates these elements:

• Focus on Gamma-Delta T Cells: IN8bio is dedicated to advancing allogeneic gamma-delta T cell therapies. This focus reflects a strategic decision to leverage the unique attributes of these cells in combating cancer.
• Innovation in Immunotherapy: The company aims to create novel and effective immunotherapies. This suggests a commitment to pushing the boundaries of cancer treatment.
• Commitment to Patients: Ultimately, IN8bio seeks to improve outcomes for cancer patients. This patient-centric approach drives the company's research and development efforts.

While a formal mission statement provides a concise articulation of a company's purpose, a deeper understanding of IN8bio's work can be gained by examining its activities and achievements. For instance, recent data from the company's clinical trials have shown promising results. IN8bio presented positive updated data from its Phase 1 trial of INB-400 in patients with newly diagnosed glioblastoma (GBM) at the American Association for Cancer Research (AACR) Annual Meeting on April 8, 2024. As of the data cutoff date of March 18, 2024, 12 patients with newly diagnosed GBM harboring the MGMT-unmethylated promoter had been treated with INB-400 after receiving standard of care chemo-radiation. The median Progression Free Survival (mPFS) was 12.0 months, and the Overall Survival (OS) was 21.9 months.

The company's focus on innovation is evident in its research and development pipeline, which includes multiple programs targeting different types of cancer. This dedication to scientific advancement is crucial in the rapidly evolving field of immunotherapy. For a deeper dive into the company's financial standing, check out: Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors

IN8bio, Inc. (INAB) Vision Statement

To fully understand where IN8bio, Inc. (INAB) is headed, examining their mission, vision, and core values is essential. These elements work together to communicate the company's purpose, aspirations, and guiding principles. As of April 2025, this alignment provides a clear picture of IN8bio's strategic direction and operational philosophy.

Mission Statement: IN8bio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies for the treatment of cancer. The company's lead programs include autologous and allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors.

Vision Statement: While a specific, stand-alone vision statement might not be explicitly declared in the traditional format, IN8bio's aspirations are evident through its actions and goals. Their vision can be inferred from their commitment to pioneering gamma-delta T cell therapies, aiming to revolutionize cancer treatment. This involves:

• Developing cutting-edge therapies: Focusing on innovative approaches to harness the power of gamma-delta T cells to combat cancer.
• Addressing unmet medical needs: Targeting cancers with limited treatment options, thereby offering new hope to patients.
• Advancing clinical research: Conducting rigorous clinical trials to demonstrate the safety and efficacy of their therapies.
• Expanding therapeutic applications: Exploring the potential of gamma-delta T cell therapies across a range of hematologic malignancies and solid tumors.

Core Values: IN8bio's core values are reflected in their dedication to scientific excellence, patient-centricity, and collaborative spirit. These values guide their daily operations and long-term strategic decisions.

Pioneering Gamma-Delta T Cell Therapies

IN8bio is at the forefront of developing gamma-delta T cell therapies, a novel approach to cancer treatment. Gamma-delta T cells possess unique properties that make them well-suited for targeting cancer cells. Unlike alpha-beta T cells, gamma-delta T cells do not require specific antigen presentation through MHC molecules, allowing them to recognize and kill a broader range of cancer cells. As of their last financial report in 2024, IN8bio is dedicated to refining and expanding the applications of these therapies.

As of the fiscal year 2024, IN8bio reported a research and development expense of $26.5 million, underscoring its commitment to pioneering gamma-delta T cell therapies. This figure highlights the company's substantial investment in advancing its innovative approach to cancer treatment.

Revolutionizing Cancer Treatment

IN8bio's vision extends beyond incremental improvements in cancer care; it aims for a fundamental shift in how cancer is treated. By leveraging the unique capabilities of gamma-delta T cells, the company seeks to develop therapies that are more effective, less toxic, and accessible to a wider range of patients. This involves:

• Enhancing efficacy: Improving the ability of gamma-delta T cells to target and eliminate cancer cells.
• Reducing toxicity: Developing therapies that minimize off-target effects and spare healthy tissues.
• Personalizing treatment: Tailoring therapies to the individual characteristics of each patient's cancer.

The company's focus on autologous and allogeneic cell therapies reflects its commitment to addressing the diverse needs of cancer patients. Autologous therapies, which use a patient's own cells, can minimize the risk of rejection, while allogeneic therapies, which use cells from a healthy donor, can provide an off-the-shelf treatment option.

In 2024, IN8bio's general and administrative expenses totaled $9.9 million, reflecting the costs associated with supporting its operations and advancing its clinical programs. This investment in administrative functions is essential for driving the company's mission of revolutionizing cancer treatment.

Addressing Unmet Medical Needs

A core aspect of IN8bio's vision is to address the significant unmet medical needs in cancer care. Many cancers remain difficult to treat, with limited therapeutic options and poor patient outcomes. IN8bio is focused on developing therapies for these challenging cancers, offering new hope to patients who have exhausted conventional treatments.

This commitment is evident in the company's pipeline, which includes programs targeting hematologic malignancies such as leukemia and lymphoma, as well as solid tumors such as ovarian cancer and glioblastoma. These cancers represent significant medical challenges, with high mortality rates and limited treatment options.

As of 2024, IN8bio held $48.9 million in cash and cash equivalents, providing the financial resources necessary to advance its pipeline and address unmet medical needs in cancer care. This strong financial position underscores the company's ability to execute its vision and bring innovative therapies to patients in need.

For more detailed insights into IN8bio, Inc. (INAB) financial health, you can explore this analysis: Breaking Down IN8bio, Inc. (INAB) Financial Health: Key Insights for Investors.

IN8bio, Inc. (INAB) Core Values of

While I don't have access to the exact mission statement, vision, and core values of IN8bio, Inc. (INAB) as of today, April 16, 2025, I can provide a framework for understanding how such values typically manifest in a company, especially one in the biotechnology sector. You can also explore more about the company's background and mission at: IN8bio, Inc. (INAB): History, Ownership, Mission, How It Works & Makes Money

Here are potential core values with examples of how IN8bio might demonstrate them:

Innovation

Innovation is critical in the biotechnology industry, where breakthroughs can lead to life-saving therapies. For IN8bio, this might mean:

• Investing a significant percentage of its revenue in Research and Development (R&D). For example, a company might allocate 15-20% of its annual revenue to R&D to explore new technologies and therapies.
• Fostering a culture of experimentation and learning from failures. This could involve internal programs that reward innovative ideas, regardless of their immediate success.
• Partnering with academic institutions and other companies to access new ideas and technologies.

Patient Focus

A commitment to patients is paramount for any healthcare company. This could translate to:

• Prioritizing the development of therapies that address unmet medical needs, particularly in areas like cancer where IN8bio is focused.
• Ensuring that clinical trials are conducted ethically and with the well-being of patients as the top priority.
• Providing patient support programs to help individuals navigate the challenges of treatment.

Integrity

Operating with the highest ethical standards is essential for building trust with patients, healthcare providers, and investors. Examples include:

• Adhering to all regulatory requirements and industry best practices.
• Maintaining transparency in research and clinical trial data.
• Ensuring that all interactions with healthcare professionals are conducted in an ethical and responsible manner.

Collaboration

Collaboration is often necessary to bring complex therapies to market. This could involve:

• Working closely with regulatory agencies like the FDA to ensure that therapies are safe and effective.
• Partnering with other companies to share resources and expertise.
• Engaging with patient advocacy groups to understand their needs and perspectives.

Excellence

Striving for excellence in all aspects of the business is crucial for success in the competitive biotechnology industry. This might mean:

• Recruiting and retaining top talent.
• Investing in state-of-the-art facilities and equipment.
• Continuously improving processes and procedures to enhance efficiency and quality.

These values, if embraced by IN8bio, would likely be reflected in their strategic decisions, operational practices, and overall culture. While specific financial data related to these values isn't directly available, their impact can be inferred from the company's investments in R&D, clinical trial outcomes, and reputation within the industry.